XML 71 R26.htm IDEA: XBRL DOCUMENT
v3.20.1

Quarterly Financial Information (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Financial Information (Unaudited) | Quarterly Financial Information (Unaudited) The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2019 and 2018 (unaudited):
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2019 |  | September 30, 2019 |  | June 30, 2019 |  | March 31, 2019
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenues: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 184,523 |  |  | $ | 617,427 |  |  | $ | 64,283 |  |  | $ | 2,770,712 |
Revenue under collaborative research and development arrangements with affiliated entities | 55,665 |  |  | 53,014 |  |  | 71,390 |  |  | 55,579 |
Miscellaneous revenue, including from affiliated entities | 39,300 |  |  | 196,422 |  |  | — |  |  | 3,614 |
Total revenues | 279,488 |  |  | 866,863 |  |  | 135,673 |  |  | 2,829,905 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 22,003,955 |  |  | 19,137,209 |  |  | 22,486,266 |  |  | 24,389,888 |
General and administrative | 8,696,586 |  |  | 5,681,441 |  |  | 5,850,101 |  |  | 6,975,029 |
Total operating expenses | 30,700,541 |  |  | 24,818,650 |  |  | 28,336,367 |  |  | 31,364,917 |
Loss from operations | (30,421,053 | ) |  | (23,951,787 | ) |  | (28,200,694 | ) |  | (28,535,012 | )
Interest income | 587,679 |  |  | 637,438 |  |  | 755,330 |  |  | 625,535 |
Interest expense | (2,668,837 | ) |  | (2,428,671 | ) |  | (2,194,783 | ) |  | (656,248 | )
Change in fair value of derivative liability | (4,315,105 | ) |  | 2,551,453 |  |  | — |  |  | — |
Loss on investment in affiliated entities | (1,681,401 | ) |  | (485,841 | ) |  | (173,212 | ) |  | (750,103 | )
Other income (expense), net | 263,571 |  |  | 140,956 |  |  | 127,512 |  |  | (35,839 | )
Net loss before income tax benefit | $ | (38,235,146 | ) |  | $ | (23,536,452 | ) |  | $ | (29,685,847 | ) |  | $ | (29,351,667 | )
Income tax benefit | 87,764 |  |  | — |  |  | 106,771 |  |  | 62,800 |
Net loss | $ | (38,147,382 | ) |  | $ | (23,536,452 | ) |  | $ | (29,579,076 | ) |  | $ | (29,288,867 | )
Net loss attributable to non-controlling interest | 485,344 |  |  | 445,759 |  |  | 191,850 |  |  | 69,605 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (37,662,038 | ) |  | $ | (23,090,693 | ) |  | $ | (29,387,226 | ) |  | $ | (29,219,262 | )
Net loss per share |  |  |  |  |  |  |
Basic | $ | (0.38 | ) |  | $ | (0.23 | ) |  | $ | (0.30 | ) |  | $ | (0.30 | )
Diluted | $ | (0.38 | ) |  | $ | (0.25 | ) |  | $ | (0.30 | ) |  | $ | (0.30 | )
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2018 |  | September 30, 2018 |  | June 30, 2018 |  | March 31, 2018
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenues: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 2,372,600 |  |  | $ | 1,813,287 |  |  | $ | 24,385,852 |  |  | $ | 1,289,046 |
Revenue under collaborative research and development arrangements with affiliated entity | 56,207 |  |  | 184,990 |  |  | 60,319 |  |  | 148,008 |
Miscellaneous revenue | 73,817 |  |  | 2,591 |  |  | 2,590 |  |  | 92,590 |
Total revenues | 2,502,624 |  |  | 2,000,868 |  |  | 24,448,761 |  |  | 1,529,644 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 26,365,647 |  |  | 21,851,858 |  |  | 22,462,620 |  |  | 24,577,751 |
General and administrative | 5,636,141 |  |  | 6,791,693 |  |  | 7,189,310 |  |  | 9,698,015 |
Total operating expenses | 32,001,788 |  |  | 28,643,551 |  |  | 29,651,930 |  |  | 34,275,766 |
Loss from operations | (29,499,164 | ) |  | (26,642,683 | ) |  | (5,203,169 | ) |  | (32,746,122 | )
Interest and other income, net | (169,300 | ) |  | 380,987 |  |  | 396,681 |  |  | 312,523 |
Change in fair value of common stock warrants | — |  |  | 228,665 |  |  | 259,971 |  |  | (127,841 | )
Gain (loss) from investment in affiliated entities | (3,293,741 | ) |  | 1,017,359 |  |  | (2,092,608 | ) |  | 2,380,423 |
Net loss before provision for income taxes | (32,962,205 | ) |  | (25,015,672 | ) |  | (6,639,125 | ) |  | (30,181,017 | )
Provision for income taxes | — |  |  | — |  |  | — |  |  | (2,169,811 | )
Net loss | (32,962,205 | ) |  | (25,015,672 | ) |  | (6,639,125 | ) |  | (32,350,828 | )
Net loss per share |  |  |  |  |  |  |
Basic | $ | (0.34 | ) |  | $ | (0.27 | ) |  | $ | (0.07 | ) |  | $ | (0.36 | )
Diluted | $ | (0.34 | ) |  | $ | (0.27 | ) |  | $ | (0.08 | ) |  | $ | (0.36 | )

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration